Testing ersodetug for low blood sugar from neuroendocrine tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new medicine called ersodetug in people whose neuroendocrine tumors cause dangerously low blood sugar that standard treatments can't control. If you need IV sugar or nutrition for at least a week, this trial may offer a new option to help manage your blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and agree to join the study.
- You have a type of tumor called a neuroendocrine tumor that causes low blood sugar.
- Standard treatments for low blood sugar have not worked well enough, and you need IV sugar or nutrition for at least 7 days.
- You must not have an active infection like HIV, hepatitis B, or hepatitis C.
- You should not have tried other experimental drugs within the last 30 days (or 5 half-lives, whichever is longer) unless the study team approves.
- Your life expectancy due to the tumor must be longer than 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an investigational drug called ersodetug for people whose low blood sugar is caused by a tumor and hasn't improved with standard care. It's designed for those who can't join a regular clinical trial for this condition.
This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.
This study helps doctors diagnose and treat dangerously low blood sugar, especially in people with pancreatic tumors that produce too much insulin. You'll receive comprehensive evaluation and personalized care to manage your condition.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Hear when a new Tumor Hyperinsulinism (Tumor HI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.